The latest immunotherapy news and developments
Results from a new phase III study found that combining PD-L1 and TIGIT inhibitors plus…
The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with…
The development of any type of second cancer following CAR T cell therapy is a…
A multi-institutional study co-authored by University of Texas at Arlington (USA) scientists uncovered a mechanism…
Cancer treatments, including chemotherapy, in addition to killing a large number of tumour cells, also…
A new research paper was published in Aging and “Aging-US” by Web of Science Volume 16, Issue…
Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain…
An innovative computational tool dubbed “SNAF” may help the research world bring the emerging promise…
At EPFL’s School of Engineering, Professor Li Tang’s Laboratory of Biomaterials for Immunoengineering has made…
Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood…